Sawgrass Asset Management LLC purchased a new stake in Amedisys Inc (NASDAQ:AMED) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 16,680 shares of the health services provider’s stock, valued at approximately $1,048,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its holdings in Amedisys by 1.5% during the second quarter. Victory Capital Management Inc. now owns 702,239 shares of the health services provider’s stock worth $44,108,000 after acquiring an additional 10,080 shares in the last quarter. UBS Asset Management Americas Inc. raised its holdings in Amedisys by 140.0% during the first quarter. UBS Asset Management Americas Inc. now owns 11,760 shares of the health services provider’s stock worth $601,000 after acquiring an additional 6,861 shares in the last quarter. OppenheimerFunds Inc. raised its holdings in Amedisys by 3.5% during the first quarter. OppenheimerFunds Inc. now owns 446,147 shares of the health services provider’s stock worth $22,794,000 after acquiring an additional 15,289 shares in the last quarter. Thrivent Financial For Lutherans raised its holdings in Amedisys by 3.8% during the first quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock worth $802,000 after acquiring an additional 570 shares in the last quarter. Finally, Ameritas Investment Partners Inc. bought a new stake in Amedisys during the first quarter worth about $123,000. Institutional investors and hedge funds own 96.55% of the company’s stock.
Several analysts recently issued reports on the company. Royal Bank Of Canada reiterated a “hold” rating and set a $56.00 target price on shares of Amedisys in a report on Monday, June 5th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Wednesday, July 26th. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Bank of America Corporation assumed coverage on Amedisys in a report on Monday, August 21st. They set a “neutral” rating and a $55.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $56.44.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/09/22/sawgrass-asset-management-llc-purchases-shares-of-16680-amedisys-inc-amed.html.
In other Amedisys news, Director Bruce D. Perkins acquired 2,000 shares of Amedisys stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the purchase, the director now owns 15,825 shares of the company’s stock, valued at $737,445. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David B. Pearce sold 1,000 shares of Amedisys stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by insiders.
Shares of Amedisys Inc (NASDAQ AMED) traded up 0.64% during trading on Friday, reaching $51.68. The company’s stock had a trading volume of 12,410 shares. The firm has a market cap of $1.75 billion, a PE ratio of 44.17 and a beta of 0.84. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The stock’s 50 day moving average price is $50.25 and its 200-day moving average price is $54.94.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 EPS. Equities analysts predict that Amedisys Inc will post $2.21 EPS for the current year.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.